⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8056839 | 0.79 | GPR119 (0.35) | — | |
| SCHEMBL11868955 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL25181056 | 0.75 | KDM4E (0.39) | — | |
| SCHEMBL25185152 | 0.75 | KDM4E (0.39) | — | |
| SCHEMBL678742 | 0.72 | — | — | |
| SCHEMBL786607 | 0.72 | HTT (0.41) | — | |
| SCHEMBL15932047 | 0.71 | GPR119 (0.43) | — | |
| SCHEMBL1091056 | 0.71 | GPR119 (0.43) | — | |
| SCHEMBL15088443 | 0.70 | — | — | |
| SCHEMBL12615284 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| EP-3468967-B1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC (CA) | 2023-07-26 | — | — | EP | disclosed |
| CN-109890814-B | Compounds comprising benzo [ D ] [1,3] oxathiolane 3-oxides and methods/uses thereof | 普拉马纳制药公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11358956-B2 | Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2022-06-14 | — | — | US | disclosed |
| WO-2021219019-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210300907-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2021-09-30 | — | — | US | disclosed |
| US-20210188825-A1 | COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2021-06-24 | — | — | US | disclosed |
| US-10906894-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2021-02-02 | — | — | US | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117421-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7582662-B2 | Body weight gain inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7572920-B2 | Benzimidazole derivative and use as a II receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-11 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | disclosed |
| US-20090054502-A1 | Benzimidazole Derivative and Use as Angiotensin II Antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-02-26 | — | — | US | disclosed |
| US-7378108-B1 | Percutaneous absorption preparation of compound having angiotensin II antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7157584-B2 | Benzimidazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |